Heart transplant waiting lists could shrink dramatically as perfusion technology transforms previously unusable donor organs into viable lifesavers. Traditional heart preservation methods have limited transplant teams to only the healthiest donor organs, leaving thousands of patients waiting for organs that never come. New perfusion systems are rewriting these limitations by keeping hearts alive and functional outside the body for extended periods. The technology works through two primary approaches: normothermic pulsatile perfusion that maintains hearts at body temperature with artificial circulation, and hypothermic non-pulsatile perfusion that preserves organs at lower temperatures. These systems allow surgeons to assess heart function in real-time, extend viable preservation windows, and rehabilitate organs from donors who died after cardiac arrest rather than brain death. Clinical trials demonstrate that perfused hearts from expanded donor criteria perform comparably to traditional transplants in both short and medium-term outcomes. The breakthrough particularly benefits donation after circulatory death cases, where hearts can be combined with whole-body perfusion techniques to maximize viability. This represents a paradigm shift from the transplant field's historical reliance on pristine donor conditions. However, the technology demands significant infrastructure investment, specialized training, and complex logistics that may limit initial adoption to major medical centers. While long-term durability data remains limited, early evidence suggests these techniques could fundamentally expand organ availability without compromising recipient outcomes, potentially addressing one of medicine's most persistent shortages.